Humacyte, INC

Humacyte, Inc. received a notification from Nasdaq regarding its common stock bid price falling below the $1.00 minimum requirement, triggering a 180-day compliance period.

Humacyte, Inc. has priced an underwritten public offering of 47,619,048 shares of its common stock at $1.05 per share to raise approximately $50 million in gross proceeds.

Humacyte's Phase 3 V012 study of its acellular tissue engineered vessel (ATEV) for dialysis access in female patients met its primary endpoint, showing superior catheter-free days compared to standard AV fistula.

Humacyte, Inc. announced the approval of an amendment to increase its authorized common stock shares from 350 million to 550 million, effective June 9, 2026.

Humacyte, Inc. has officially regained compliance with Nasdaq's minimum bid price requirement for continued listing.

Humacyte, Inc. has been notified by Nasdaq that its common stock has fallen below the minimum $1.00 bid price requirement for continued listing.

Humacyte, Inc. reported a significant reduction in net loss and its first product revenue from Symvess sales, while navigating increased cash burn and multiple legal proceedings.

Humacyte reports initial Symvess product revenue and reduced operating losses in Q2 2025, alongside strategic cost reductions and ongoing clinical trial progress, despite a denied NTAP application and persistent legal challenges.

Humacyte, Inc. reports its first quarter 2025 financial results, highlighted by the commencement of the commercial launch of its ATEV product, Symvess, for vascular trauma.

Humacyte's Q3 2024 results reveal increased operating losses and a going concern warning due to delayed FDA review and the need for additional capital.

Humacyte's Q2 2024 results show increased operating losses and a net loss, alongside concerns about the company's ability to continue as a going concern due to delayed FDA review and funding requirements.

Humacyte's Q1 2024 results show increased R&D spending and a net loss, alongside a successful public offering and a revenue interest purchase agreement installment.

Humacyte, Inc. commenced U.S. commercial sales of its FDA-approved Symvess for vascular trauma in Q1 2025, generating $1.4 million in revenue, but faces substantial doubt about its ability to continue as a going concern.

Humacyte, Inc. announced FDA approval for its bioengineered tissue product Symvess for extremity vascular trauma and initiated its U.S. commercial launch in Q1 2025, while continuing Phase 3 trials for other indications and securing significant financing.

Humacyte's 10-K filing provides a detailed description of its capital stock, including common and preferred shares, as well as the terms of outstanding warrants.

Director Susan Richards Windham-Bannister was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation arrangement.

Director Michael T. Constantino was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Director Max N. Wallace was granted 80,000 stock options in Humacyte, Inc. with an exercise price of $1.08.

Humacyte CEO Laura E. Niklason reported a grant of 80,000 stock options to her spouse.

Director Kathleen Sebelius was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Director Keith Anthony Jones was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation plan.

Humacyte, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect directors, approve executive compensation, ratify auditor selection, and vote on a significant increase in authorized shares.

Humacyte, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Humacyte is asking stockholders to approve an amendment to its corporate charter to increase the number of authorized common shares from 250 million to 350 million at the upcoming annual meeting.

Humacyte, Inc. has filed a definitive proxy statement with the SEC.

Humacyte, Inc. announces its annual meeting of stockholders to be held virtually on June 11, 2024, with key proposals including the election of directors and ratification of the company's independent accounting firm.

Fresenius Medical Care Holdings, Inc. has established a Rule 10b5-1 trading plan to sell up to 5 million shares of Humacyte, Inc. common stock.

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG have filed an amendment to their Schedule 13D, updating their beneficial ownership of Humacyte, Inc. common stock to 6.8%.

Humacyte, Inc. and Fresenius Medical Care Holdings, Inc. have amended their distribution agreement, granting Humacyte exclusive global rights to distribute Symvess(R) outside the U.S. in exchange for low-single-digit royalties.

Fresenius Medical Care's beneficial ownership in Humacyte, Inc. decreased to 8.4% due to share dilution, not share sales.

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG updated their Schedule 13D filing for Humacyte, Inc., reporting a decreased beneficial ownership percentage due to share dilution and announcing key management changes within Fresenius.

Fresenius Medical Care AG's beneficial ownership in Humacyte, Inc. decreased to 9.9% due to share dilution, while announcing a new CEO for its Care Enablement segment.